Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Compass Therapeutics reports Q1 EPS (7c), consensus (12c) » 08:05
05/09/22
05/09
08:05
05/09/22
08:05
CMPX

Compass Therapeutics

$1.69 /

+0.19 (+12.67%)

As of March 31, 2022,…

As of March 31, 2022, cash and cash equivalents were $136.4 million as compared to $39.7 million as of March 31, 2021, providing the Company with an anticipated cash runway into the second half of 2024. The Company used $7.9 million of cash to fund operations in the first quarter of 2022.

ShowHide Related Items >><<
CMPX Compass Therapeutics
$1.69 /

+0.19 (+12.67%)

CMPX Compass Therapeutics
$1.69 /

+0.19 (+12.67%)

03/15/22 Ladenburg
Compass Therapeutics initiated with a Buy at Ladenburg
01/19/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
01/18/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
CMPX Compass Therapeutics
$1.69 /

+0.19 (+12.67%)

  • 02
    Nov
CMPX Compass Therapeutics
$1.69 /

+0.19 (+12.67%)

Hot Stocks
Compass Therapeutics reports interim Phase 2 data of CTX-009 » 07:25
05/04/22
05/04
07:25
05/04/22
07:25
CMPX

Compass Therapeutics

$1.51 /

+0.055 (+3.78%)

Compass Therapeutics…

Compass Therapeutics reported additional interim results from a Phase 2 study of CTX-009 in combination with paclitaxel in patients with biliary tract cancers. The data show that: CTX-009 demonstrated a 42% overall response rate based on 10 patients with Partial Responses, including 9 PRs confirmed by RECIST 1.1 and 1 PR pending confirmation; CTX-009 demonstrated anti-tumor activity in previously treated patients with a clinical benefit rate of 92% based on 22 patients with a PR or stable disease out of 24 enrolled patients; CTX-009 was well-tolerated and preliminary safety profile is consistent with prior studies. The Phase 2 study has a Simon Two-Stage adaptive design where three PRs among the first 21 patients enrolled in the first stage of the study will advance the study to the second stage. In November 2021, Compass reported that there were five PRs observed among the first 17 evaluable patients, and therefore, the criteria to advance the study to its second stage was met. The study is currently being conducted at four leading medical centers in Korea. In the United States, an IND was opened in January of 2022 and first patient dose is projected to take place in early Q3 2022. All patients enrolled in the study had BTC, classified into four subgroups: intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer and ampullary cancer. As of the data cut-off date April 14, 2022, 24 patients were enrolled and dosed with at least one cycle of CTX-009 and paclitaxel, and 22 were evaluable for response. All patients enrolled in the study have advanced BTC; 45.8% of the patients received one prior therapy and 54.2% of the patients received at least two prior therapies. Almost all patients received gemcitabine/cisplatin. Patients had a median age of 61.5 years, an ECOG performance status of 0 or 1. CTX-009 exhibited a 42% ORR based on 10 patients with PRs, including nine confirmed PRs by RECIST 1.1 and one PR pending confirmation. Two patients were not evaluable for the purpose of efficacy, and 22 of the 24 patients have had stable disease or better observed leading to a CBR of 92%. As of the cutoff date, seven patients were continuing to receive treatment, including five patients who had been on treatment for over nine months. CTX-009, in combination with paclitaxel, continues to be well tolerated, consistent with the Phase 1 studies, with hypertension and neutropenia being the most common events related to CTX-009 and paclitaxel, respectively. Of the 24 subjects enrolled in the study, all subjects had at least one AE related to CTX-009 and/or paclitaxel. The most common adverse events occurring in at least three patients were anemia, asthenia, fatigue, edema, pyrexia, neutropenia, thrombocytopenia, headache, proteinuria, dysphonia, dyspnea, epistaxis, pulmonary hypertension and hypertension. Grade 3 or greater treatment-emergent adverse events occurring in more than one patient include neutropenia, hypertension, anemia and thrombocytopenia; all TEAEs were manageable with standard treatment.

ShowHide Related Items >><<
CMPX Compass Therapeutics
$1.51 /

+0.055 (+3.78%)

CMPX Compass Therapeutics
$1.51 /

+0.055 (+3.78%)

03/15/22 Ladenburg
Compass Therapeutics initiated with a Buy at Ladenburg
01/19/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
01/18/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
CMPX Compass Therapeutics
$1.51 /

+0.055 (+3.78%)

  • 02
    Nov
CMPX Compass Therapeutics
$1.51 /

+0.055 (+3.78%)

Hot Stocks
Compass Therapeutics appoints Ellen Chiniara, Mary Ann Gray to board » 08:27
04/26/22
04/26
08:27
04/26/22
08:27
CMPX

Compass Therapeutics

$1.49 /

-0.1 (-6.29%)

, ALXN

Alexion

$182.40 /

+ (+0.00%)

Compass Therapeutics…

Compass Therapeutics (CMPX) is pleased to announce the appointment of two new directors to its board. Joining the board of directors are Ellen Chiniara, JD, former Chief Legal Officer of Alexion (ALXN) Pharmaceuticals, and Mary Ann Gray, PhD, President of Gray Strategic Advisors

ShowHide Related Items >><<
CMPX Compass Therapeutics
$1.49 /

-0.1 (-6.29%)

ALXN Alexion
$182.40 /

+ (+0.00%)

CMPX Compass Therapeutics
$1.49 /

-0.1 (-6.29%)

03/15/22 Ladenburg
Compass Therapeutics initiated with a Buy at Ladenburg
01/19/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
01/18/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
ALXN Alexion
$182.40 /

+ (+0.00%)

09/29/21 H.C. Wainwright
H.C. Wainwright says Astra deal for Caelum to yield 'nice check' for Fortress
09/23/21 Gordon Haskett
Gordon Haskett compares Incyte to Alexion before Astra buyout
08/04/21 SVB Leerink
AstraZeneca price target raised to $69 from $63 at SVB Leerink
05/05/21
Fly Intel: Top five analyst upgrades
CMPX Compass Therapeutics
$1.49 /

-0.1 (-6.29%)

  • 02
    Nov
CMPX Compass Therapeutics
$1.49 /

-0.1 (-6.29%)

Over a month ago
Hot Stocks
Compass Therapeutics presents data on CTX-8371 at AACR meeting » 13:08
04/08/22
04/08
13:08
04/08/22
13:08
CMPX

Compass Therapeutics

$1.58 /

-0.05 (-3.07%)

Compass Therapeutics…

Compass Therapeutics reported new preclinical data on CTX-8371, a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 and exhibits a unique MOA that involves cleavage of cell surface PD-1, at the American Association for Cancer Research, or AACR, Annual Meeting, which is being held April 8-13. Key data presented includes the following: Treatment with CTX-8371 leads to PD-1 loss from the surface of intra-tumoral T cells in tumor-bearing transgenic hPD-1/h-PD-L1 mice, and on peripheral blood T cells in cynomolgus macaques. This unique mechanism of action differentiates CTX-8371 from marketed inhibitors targeting either PD-1 or PD-L1; Clearance and half-life of CTX-8371 are within the expected ranges for a human IgG1 antibody in non-human primates with a linear PK; Treatment with CTX-8371 in the aggressive MC38-hPD-L1 colorectal mouse model led to a dose-proportional reduction in tumor volume and a complete eradication of tumors at the highest dose. "Taken together, the murine and cynomolgus monkey PK data, receptor occupancy data, and in vivo efficacy data in murine models will be used to calculate the predicted human efficacious dose range for CTX-8371," the company said. "These findings further provide in vivo evidence for the differentiated mechanism of action of CTX-8371 and inform its clinical development, which is projected to begin in the first half of 2023," said Thomas Schuetz, MD, PhD, CEO and Scientific Founder of Compass Therapeutics.

ShowHide Related Items >><<
CMPX Compass Therapeutics
$1.58 /

-0.05 (-3.07%)

CMPX Compass Therapeutics
$1.58 /

-0.05 (-3.07%)

03/15/22 Ladenburg
Compass Therapeutics initiated with a Buy at Ladenburg
01/19/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
01/18/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
CMPX Compass Therapeutics
$1.58 /

-0.05 (-3.07%)

  • 02
    Nov
CMPX Compass Therapeutics
$1.58 /

-0.05 (-3.07%)

Hot Stocks
Compass Therapeutics announces presentation on CTX-8371 at 2022 AACR meeting » 08:04
03/30/22
03/30
08:04
03/30/22
08:04
CMPX

Compass Therapeutics

$1.26 /

+0.01 (+0.80%)

Compass Therapeutics…

Compass Therapeutics announced that it will present preclinical data on CTX-8371, a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 at the upcoming American Association for Cancer Research, AACR, Annual Meeting, which is being held April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Presentation Title: "Dose Range Finding Study in Non-human Primates Confirms the Unique Mechanism of Action of CTX-8371, a Novel Bispecific Antibody Blocking PD-1 and PD-L1."

ShowHide Related Items >><<
CMPX Compass Therapeutics
$1.26 /

+0.01 (+0.80%)

CMPX Compass Therapeutics
$1.26 /

+0.01 (+0.80%)

03/15/22 Ladenburg
Compass Therapeutics initiated with a Buy at Ladenburg
01/19/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
01/18/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
CMPX Compass Therapeutics
$1.26 /

+0.01 (+0.80%)

  • 02
    Nov
CMPX Compass Therapeutics
$1.26 /

+0.01 (+0.80%)

Hot Stocks
Compass Therapeutics expects cash to fund operations into H2 of 2024 » 08:03
03/21/22
03/21
08:03
03/21/22
08:03
CMPX

Compass Therapeutics

$1.25 /

-0.16 (-11.35%)

As of December 31, 2021,…

As of December 31, 2021, cash and cash equivalents were $144.5M as compared to $47.1M as of December 31, 2020, providing the Company with an anticipated cash runway into the second half of 2024.

ShowHide Related Items >><<
CMPX Compass Therapeutics
$1.25 /

-0.16 (-11.35%)

CMPX Compass Therapeutics
$1.25 /

-0.16 (-11.35%)

03/15/22 Ladenburg
Compass Therapeutics initiated with a Buy at Ladenburg
01/19/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
01/18/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
CMPX Compass Therapeutics
$1.25 /

-0.16 (-11.35%)

  • 02
    Nov
CMPX Compass Therapeutics
$1.25 /

-0.16 (-11.35%)

Earnings
Compass Therapeutics reports Q4 EPS (15c), consensus (7c) » 08:03
03/21/22
03/21
08:03
03/21/22
08:03
CMPX

Compass Therapeutics

$1.25 /

-0.16 (-11.35%)

"In 2021 we…

"In 2021 we strengthened our pipeline of innovative antibody-based therapeutics with the addition of CTX-009, a novel bispecific antibody targeting DLL4 and VEGF-A, two important signaling molecules in the angiogenesis pathways. We are excited to see the activity of CTX-009 across multiple solid tumors and happy to report that the criteria to advance our Global Phase 2 study to its second stage have already been met," said Thomas Schuetz, MD, PhD, Co-Founder and Chief Executive Officer.

ShowHide Related Items >><<
CMPX Compass Therapeutics
$1.25 /

-0.16 (-11.35%)

CMPX Compass Therapeutics
$1.25 /

-0.16 (-11.35%)

03/15/22 Ladenburg
Compass Therapeutics initiated with a Buy at Ladenburg
01/19/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
01/18/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
  • 02
    Nov
CMPX Compass Therapeutics
$1.25 /

-0.16 (-11.35%)

Initiation
Compass Therapeutics initiated with a Buy at Ladenburg » 07:34
03/15/22
03/15
07:34
03/15/22
07:34
CMPX

Compass Therapeutics

$1.45 /

-0.075 (-4.92%)

Ladenburg analyst Aydin…

Ladenburg analyst Aydin Huseynov initiated coverage of Compass Therapeutics with a Buy rating and $7 price target. Compass' bi-specific VEGF/DLL4 antibody, CTX-009, "has all it takes to get an accelerated approval" from the FDA based on a single-arm trial in the second-line cholangiocarcinoma, or CCA, indication, Huseynov tells investors. CTX-009 has shown promising responses in CCA and colorectal cancer, or CRC, indications, but he is "particularly encouraged" by the responses in the CCA indication and the potential path for accelerated approval in 2025, Huseynov said.

ShowHide Related Items >><<
CMPX Compass Therapeutics
$1.45 /

-0.075 (-4.92%)

CMPX Compass Therapeutics
$1.45 /

-0.075 (-4.92%)

01/19/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
01/18/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
12/22/21 Raymond James
Compass Therapeutics initiated with an Outperform at Raymond James
  • 02
    Nov
CMPX Compass Therapeutics
$1.45 /

-0.075 (-4.92%)

Over a quarter ago
Conference/Events
B. Riley to hold a virtual conference » 09:21
01/27/22
01/27
09:21
01/27/22
09:21
SPPI

Spectrum

/

+

, GTBP

GT Biopharma

$3.17 /

+0.24 (+8.19%)

, LPTX

Leap Therapeutics

$1.91 /

-0.07 (-3.54%)

, TGTX

TG Therapeutics

$13.88 /

-0.89 (-6.03%)

, INFI

Infinity Pharmaceuticals

$1.19 /

-0.015 (-1.24%)

, VOR

Vor Bio

$7.90 /

-0.3 (-3.66%)

, ALLO

Allogene Therapeutics

$11.23 /

-0.115 (-1.01%)

, INAB

In8bio

$3.30 /

+0.08 (+2.48%)

, CMPX

Compass Therapeutics

$1.95 /

-0.105 (-5.11%)

, SNDX

Syndax

$15.96 /

-0.48 (-2.92%)

, INKT

MiNK Therapeutics

$3.00 /

-0.09 (-2.91%)

, ROIV

Roivant Sciences

$7.49 /

+0.24 (+3.31%)

, AGEN

Agenus

$2.62 /

-0.07 (-2.60%)

, ATNM

Actinium Pharmaceuticals

$5.37 /

-0.27 (-4.79%)

, GRTS

Gritstone

$5.06 /

-0.12 (-2.32%)

, CRIS

Curis

$3.13 /

-0.09 (-2.80%)

, FUSN

Fusion Pharmaceuticals

$7.45 /

-0.52 (-6.52%)

, LCTX

Lineage Cell Therapeutics

$1.51 /

-0.12 (-7.36%)

, GRCL

Gracell

$3.49 /

-0.265 (-7.07%)

, NGM

NGM Biopharmaceuticals

$14.52 /

-0.25 (-1.69%)

, SRNE

Sorrento Therapeutics

$3.27 /

-0.245 (-6.97%)

, CMRX

Chimerix

$5.55 /

-0.13 (-2.29%)

, IDYA

Ideaya Biosciences

$15.74 /

-0.44 (-2.72%)

, RAIN

Rain Therapeutics

$8.44 /

-0.82 (-8.86%)

, TLSA

Tiziana Life Sciences

/

+

Virtual Oncology…

Virtual Oncology Conference to be held on January 27-28. Webcast Link

ShowHide Related Items >><<
VOR Vor Bio
$7.90 /

-0.3 (-3.66%)

TLSA Tiziana Life Sciences
/

+

TGTX TG Therapeutics
$13.88 /

-0.89 (-6.03%)

SRNE Sorrento Therapeutics
$3.27 /

-0.245 (-6.97%)

SPPI Spectrum
/

+

SNDX Syndax
$15.96 /

-0.48 (-2.92%)

ROIV Roivant Sciences
$7.49 /

+0.24 (+3.31%)

RAIN Rain Therapeutics
$8.44 /

-0.82 (-8.86%)

NGM NGM Biopharmaceuticals
$14.52 /

-0.25 (-1.69%)

LPTX Leap Therapeutics
$1.91 /

-0.07 (-3.54%)

LCTX Lineage Cell Therapeutics
$1.51 /

-0.12 (-7.36%)

INKT MiNK Therapeutics
$3.00 /

-0.09 (-2.91%)

INFI Infinity Pharmaceuticals
$1.19 /

-0.015 (-1.24%)

INAB In8bio
$3.30 /

+0.08 (+2.48%)

IDYA Ideaya Biosciences
$15.74 /

-0.44 (-2.72%)

GTBP GT Biopharma
$3.17 /

+0.24 (+8.19%)

GRTS Gritstone
$5.06 /

-0.12 (-2.32%)

GRCL Gracell
$3.49 /

-0.265 (-7.07%)

FUSN Fusion Pharmaceuticals
$7.45 /

-0.52 (-6.52%)

CRIS Curis
$3.13 /

-0.09 (-2.80%)

CMRX Chimerix
$5.55 /

-0.13 (-2.29%)

CMPX Compass Therapeutics
$1.95 /

-0.105 (-5.11%)

ATNM Actinium Pharmaceuticals
$5.37 /

-0.27 (-4.79%)

ALLO Allogene Therapeutics
$11.23 /

-0.115 (-1.01%)

AGEN Agenus
$2.62 /

-0.07 (-2.60%)

SPPI Spectrum
/

+

08/18/21 B. Riley
Spectrum price target lowered to $6 from $8 at B. Riley
06/01/21 H.C. Wainwright
H.C. Wainwright remains bullish on Spectrum as FDA inspects Rolontis facility
GTBP GT Biopharma
$3.17 /

+0.24 (+8.19%)

01/24/22 B. Riley
GT Biopharma price target lowered to $18 from $26 at B. Riley
06/24/21 B. Riley
GT Biopharma price target raised to $26 from $21 at B. Riley
05/24/21 H.C. Wainwright
GT Biopharma initiated with a Buy at H.C. Wainwright
04/13/21 B. Riley
B. Riley starts GT Biopharma with Buy, sees 101% upside in shares
LPTX Leap Therapeutics
$1.91 /

-0.07 (-3.54%)

01/23/22 Piper Sandler
Piper ups Leap Therapeutics target to $6 following DKN-01's ASCO GI Update
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
10/04/21 Mizuho
Leap Therapeutics initiated with a Buy at Mizuho
09/19/21 Piper Sandler
Piper Sandler keeps Overweight on Leap Therapeutics, ups target to $5
TGTX TG Therapeutics
$13.88 /

-0.89 (-6.03%)

01/21/22 H.C. Wainwright
TG Therapeutics price target lowered to $70 from $75 at H.C. Wainwright
12/01/21 B. Riley
TG Therapeutics selloff yesterday may be unwarranted, says B. Riley
12/01/21 Evercore ISI
TG Therapeutics price target lowered to $36 from $55 at Evercore ISI
12/01/21 Cantor Fitzgerald
TG Therapeutics price target lowered to $54 from $70 at Cantor Fitzgerald
INFI Infinity Pharmaceuticals
$1.19 /

-0.015 (-1.24%)

01/24/22 B. Riley
Infinity Pharmaceuticals price target lowered to $5 from $7 at B. Riley
12/16/21 B. Riley
Infinity Pharmaceuticals price target raised to $7 from $4 at B. Riley
12/10/21 Piper Sandler
Infinity Pharmaceuticals presents updated Phase II data, says Piper Sandler
10/18/21 H.C. Wainwright
Infinity Pharmaceuticals initiated with a Buy at H.C. Wainwright
VOR Vor Bio
$7.90 /

-0.3 (-3.66%)

01/24/22 B. Riley
Vor Biopharma price target lowered to $46 from $60 at B. Riley
12/17/21 H.C. Wainwright
Vor Biopharma initiated with a Buy at H.C. Wainwright
12/03/21 Baird
Baird start Vor Biopharma with an Outperform ahead of AML data
12/02/21 Baird
Vor Biopharma initiated with an Outperform at Baird
ALLO Allogene Therapeutics
$11.23 /

-0.115 (-1.01%)

01/10/22 Stifel
Allogene ASH update may be weighing on shares despite holds lifted, says Stifel
01/06/22 Wells Fargo
Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16
01/03/22 Guggenheim
Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
01/03/22 B. Riley
iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
INAB In8bio
$3.30 /

+0.08 (+2.48%)

01/24/22 B. Riley
In8bio price target lowered to $9 from $19 at B. Riley
08/24/21 Mizuho
In8bio initiated with a Buy at Mizuho
08/23/21 B. Riley
In8bio initiated with a Buy on cancer potential at B. Riley
08/23/21 B. Riley
In8bio initiated with a Buy at B. Riley
CMPX Compass Therapeutics
$1.95 /

-0.105 (-5.11%)

01/19/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
01/18/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
12/22/21 Raymond James
Compass Therapeutics initiated with an Outperform at Raymond James
SNDX Syndax
$15.96 /

-0.48 (-2.92%)

12/15/21 Citi
Syndax price target raised to $28 from $22 at Citi
09/28/21 B. Riley
Syndax collaboration 'significant vote of confidence,' says B. Riley
09/27/21 Stifel
Incyte's in-licensing of axatilimab 'a strategically sound move,' says Stifel
06/03/21 Baird
Syndax transferred with Outperform at Baird
INKT MiNK Therapeutics
$3.00 /

-0.09 (-2.91%)

01/24/22 B. Riley
MiNK Therapeutics price target lowered to $10 from $24 at B. Riley
11/09/21 Evercore ISI
Evercore starts Agenus spinout MiNK Therapeutics with an Outperform
11/09/21 B. Riley
MiNK Therapeutics initiated with Buy, $24 target at B. Riley
11/09/21 William Blair
William Blair starts MiNK at Outperform ahead of 'numerous catalysts'
ROIV Roivant Sciences
$7.49 /

+0.24 (+3.31%)

12/15/21 Goldman Sachs
Roivant Sciences initiated with a Buy at Goldman Sachs
12/02/21 H.C. Wainwright
H.C. Wainwright says Arbutus patent win may mean 'considerable gain' for Roivant
11/08/21 H.C. Wainwright
Roivant Sciences initiated with a Buy at H.C. Wainwright
10/27/21 Citi
Roivant Sciences initiated with a Buy at Citi
AGEN Agenus
$2.62 /

-0.07 (-2.60%)

12/16/21 H.C. Wainwright
Agenus initiated with a Buy at H.C. Wainwright
12/06/21 B. Riley
B. Riley bullish on Novavax, Agenus amid Omicron spread
10/25/21 B. Riley
Agenus price target lowered to $11 from $12 at B. Riley
ATNM Actinium Pharmaceuticals
$5.37 /

-0.27 (-4.79%)

09/15/21 Alliance Global Partners
Actinium price target lowered to $20 from $25 at Alliance Global Partners
08/03/21 H.C. Wainwright
Actinium Pharmaceuticals price target lowered to $45 from $57 at H.C. Wainwright
04/06/21 William Blair
Actinium's Q4 net loss roughly in line with projected loss, says William Blair
GRTS Gritstone
$5.06 /

-0.12 (-2.32%)

10/14/21 BTIG
Gritstone assumed with a Buy at BTIG
CRIS Curis
$3.13 /

-0.09 (-2.80%)

10/13/21
Fly Intel: Top five analyst initiations
10/13/21 Raymond James
Curis initiated with an Outperform at Raymond James
05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
FUSN Fusion Pharmaceuticals
$7.45 /

-0.52 (-6.52%)

10/19/21 Morgan Stanley
Fusion Pharmaceuticals assumed with an Overweight at Morgan Stanley
08/26/21 B. Riley
B. Riley starts Fusion Pharmaceuticals with Buy, sees over 100% upside
08/26/21 B. Riley
Fusion Pharmaceuticals initiated with a Buy at B. Riley
LCTX Lineage Cell Therapeutics
$1.51 /

-0.12 (-7.36%)

08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
GRCL Gracell
$3.49 /

-0.265 (-7.07%)

06/14/21 Piper Sandler
Gracell plans to expand GC012F's clinical profile, says Piper Sandler
06/07/21 Citi
Gracell valuation provides attractive entry point, says Citi
06/04/21 Piper Sandler
Piper sees 'clear line of sight for value creation' at Gracell after ASCO
04/30/21 Piper Sandler
Gracell transferred with Overweight rating at Piper Sandler
NGM NGM Biopharmaceuticals
$14.52 /

-0.25 (-1.69%)

01/07/22 Piper Sandler
NGM Biopharmaceuticals price target raised to $32 from $30 at Piper Sandler
09/16/21 BMO Capital
NGM Biopharmaceuticals price target raised to $35 from $29 at BMO Capital
09/12/21 Raymond James
NGM Biopharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
09/10/21 B. Riley
Mixed data from Apellis supports NGM bull thesis, says B. Riley
SRNE Sorrento Therapeutics
$3.27 /

-0.245 (-6.97%)

12/28/21 H.C. Wainwright
H.C. Wainwright reiterates $26 target on Sorrento after Covistix news
08/09/21 H.C. Wainwright
Sorrento Therapeutics price target lowered to $26 from $30 at H.C. Wainwright
03/26/21 B. Riley
Sorrento data make case for expedited EUA filing path, says B. Riley Securities
01/29/21 B. Riley
Sorrento Therapeutics initiated with a Buy at B. Riley Securities
CMRX Chimerix
$5.55 /

-0.13 (-2.29%)

12/22/21 H.C. Wainwright
Chimerix price target raised to $24 from $21 at H.C. Wainwright
11/22/21 H.C. Wainwright
Chimerix price target raised to $21 from $19 at H.C. Wainwright
06/07/21 H.C. Wainwright
Chimerix price target raised to $19 from $18 at H.C. Wainwright
05/06/21 H.C. Wainwright
Chimerix price target raised to $18 from $16 at H.C. Wainwright
IDYA Ideaya Biosciences
$15.74 /

-0.44 (-2.72%)

01/06/22 Northland
Ideaya Biosciences named a top pick for 2022 at Northland
01/03/22 Guggenheim
ImmunoGen, Merus named 'Best Ideas' in oncology-focused biotech at Guggenheim
12/08/21 Roth Capital
Ideaya Biosciences price target raised to $42 from $38 at Roth Capital
09/22/21 Stifel
Ideaya Biosciences initiated with a Hold at Stifel
RAIN Rain Therapeutics
$8.44 /

-0.82 (-8.86%)

01/03/22 Guggenheim
Rain Therapeutics price target lowered to $20 from $26 at Guggenheim
11/10/21 Piper Sandler
Rain Therapeutics price target raised to $26 from $25 at Piper Sandler
09/14/21
Fly Intel: Top five analyst downgrades
09/14/21 Goldman Sachs
Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs
TLSA Tiziana Life Sciences
/

+

01/24/22 B. Riley
Tiziana Life Sciences price target lowered to $3 from $8 at B. Riley
VOR Vor Bio
$7.90 /

-0.3 (-3.66%)

TGTX TG Therapeutics
$13.88 /

-0.89 (-6.03%)

SRNE Sorrento Therapeutics
$3.27 /

-0.245 (-6.97%)

SPPI Spectrum
/

+

SNDX Syndax
$15.96 /

-0.48 (-2.92%)

ROIV Roivant Sciences
$7.49 /

+0.24 (+3.31%)

RAIN Rain Therapeutics
$8.44 /

-0.82 (-8.86%)

NGM NGM Biopharmaceuticals
$14.52 /

-0.25 (-1.69%)

LPTX Leap Therapeutics
$1.91 /

-0.07 (-3.54%)

LCTX Lineage Cell Therapeutics
$1.51 /

-0.12 (-7.36%)

INFI Infinity Pharmaceuticals
$1.19 /

-0.015 (-1.24%)

IDYA Ideaya Biosciences
$15.74 /

-0.44 (-2.72%)

GTBP GT Biopharma
$3.17 /

+0.24 (+8.19%)

GRTS Gritstone
$5.06 /

-0.12 (-2.32%)

GRCL Gracell
$3.49 /

-0.265 (-7.07%)

FUSN Fusion Pharmaceuticals
$7.45 /

-0.52 (-6.52%)

CRIS Curis
$3.13 /

-0.09 (-2.80%)

CMRX Chimerix
$5.55 /

-0.13 (-2.29%)

ALLO Allogene Therapeutics
$11.23 /

-0.115 (-1.01%)

AGEN Agenus
$2.62 /

-0.07 (-2.60%)

  • 16
    Dec
  • 02
    Nov
  • 15
    Oct
  • 22
    Sep
  • 15
    Sep
  • 30
    Jul
  • 08
    Jul
  • 23
    Apr
  • 12
    Feb
  • 11
    Feb
  • 05
    Feb
SPPI Spectrum
/

+

LCTX Lineage Cell Therapeutics
$1.51 /

-0.12 (-7.36%)

TGTX TG Therapeutics
$13.88 /

-0.89 (-6.03%)

SRNE Sorrento Therapeutics
$3.27 /

-0.245 (-6.97%)

SPPI Spectrum
/

+

SNDX Syndax
$15.96 /

-0.48 (-2.92%)

ROIV Roivant Sciences
$7.49 /

+0.24 (+3.31%)

LPTX Leap Therapeutics
$1.91 /

-0.07 (-3.54%)

INKT MiNK Therapeutics
$3.00 /

-0.09 (-2.91%)

INFI Infinity Pharmaceuticals
$1.19 /

-0.015 (-1.24%)

INAB In8bio
$3.30 /

+0.08 (+2.48%)

GRTS Gritstone
$5.06 /

-0.12 (-2.32%)

GRCL Gracell
$3.49 /

-0.265 (-7.07%)

CRIS Curis
$3.13 /

-0.09 (-2.80%)

CMRX Chimerix
$5.55 /

-0.13 (-2.29%)

CMPX Compass Therapeutics
$1.95 /

-0.105 (-5.11%)

ALLO Allogene Therapeutics
$11.23 /

-0.115 (-1.01%)

AGEN Agenus
$2.62 /

-0.07 (-2.60%)

SRNE Sorrento Therapeutics
$3.27 /

-0.245 (-6.97%)

SPPI Spectrum
/

+

ROIV Roivant Sciences
$7.49 /

+0.24 (+3.31%)

LPTX Leap Therapeutics
$1.91 /

-0.07 (-3.54%)

INFI Infinity Pharmaceuticals
$1.19 /

-0.015 (-1.24%)

GRTS Gritstone
$5.06 /

-0.12 (-2.32%)

CRIS Curis
$3.13 /

-0.09 (-2.80%)

ALLO Allogene Therapeutics
$11.23 /

-0.115 (-1.01%)

AGEN Agenus
$2.62 /

-0.07 (-2.60%)

Hot Stocks
Compass Therapeutics announces FDA clearance of IND application for CTX-009 » 08:31
01/20/22
01/20
08:31
01/20/22
08:31
CMPX

Compass Therapeutics

$2.83 /

+0.08 (+2.91%)

Compass Therapeutics…

Compass Therapeutics announced that the U.S. Food and Drug Administration, FDA, has cleared its IND application for CTX-009, enabling the company to initiate a global Phase 2 clinical trial for CTX-009 in patients who have advanced Biliary Tract Cancers, BTC, in the United States and South Korea. Compass plans to include the existing Phase 2 in South Korea in this global study, allowing it to expand the ongoing study of CTX-009 under this IND. "We are extremely pleased to announce today the FDA has accepted our IND application for CTX-009. We thank the reviewers at the FDA for their review and comments on the Phase 2 study design," said Thomas Schuetz, MD, PhD, CEO and Scientific Founder of Compass. "The ongoing Phase 2 study in South Korea will now be expanded to a global study with the opening of US clinical sites in Q2. We believe that CTX-009 has the potential to be an important new therapy for patients with biliary tract cancers, including cholangiocarcinomas," added Dr. Schuetz.

ShowHide Related Items >><<
CMPX Compass Therapeutics
$2.83 /

+0.08 (+2.91%)

CMPX Compass Therapeutics
$2.83 /

+0.08 (+2.91%)

01/19/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
01/18/22 B. Riley
Compass Therapeutics initiated with a Buy at B. Riley
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
12/22/21 Raymond James
Compass Therapeutics initiated with an Outperform at Raymond James
  • 02
    Nov
CMPX Compass Therapeutics
$2.83 /

+0.08 (+2.91%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.